Please use this identifier to cite or link to this item:
|Title:||Platelet miRNA Biosignature Discriminates between Dementia with Lewy Bodies and Alzheimer’s Disease|
|Author:||Gámez Valero, Ana|
Campdelacreu i Fumadó, Jaume
Gascón Bayarri, Jordi
Reñé Ramírez, Ramon
Armengol, Maria P.
Borràs, Francesc E.
|Abstract:||Dementia with Lewy bodies (DLB) is one of the most common causes of degenerative dementia, after Alzheimer's disease (AD), and presents pathological and clinical overlap with both AD and Parkinson's disease (PD). Consequently, only one in three DLB cases is diagnosed correctly. Platelets, previously related to neurodegeneration, contain microRNAs (miRNAs) whose analysis may provide disease biomarkers. Here, we profiled the whole platelet miRNA transcriptome from DLB patients and healthy controls. Differentially expressed miRNAs were further validated in three consecutive studies from 2017 to 2019 enrolling 162 individuals, including DLB, AD, and PD patients, and healthy controls. Results comprised a seven-miRNA biosignature, showing the highest diagnostic potential for the differentiation between DLB and AD. Additionally, compared to controls, two miRNAs were down-regulated in DLB, four miRNAs were up-regulated in AD, and two miRNAs were down-regulated in PD. Predictive target analysis identified three disease-specific clusters of pathways as a result of platelet-miRNA deregulation. Our cross-sectional study assesses the identification of a novel, highly specific and sensitive platelet-associated miRNA-based biosignature, which distinguishes DLB from AD.|
|Note:||Reproducció del document publicat a: https://doi.org/10.3390/biomedicines9091272|
|It is part of:||Biomedicines, 2021, vol. 9, num. 9, p. 1272|
|Appears in Collections:||Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))|
This item is licensed under a Creative Commons License